Navigation Links
Idenix Reports Advancement of HCV Development Pipeline
Date:1/9/2012

CAMBRIDGE, Mass., Jan. 9, 2012 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the advancement of its hepatitis C virus (HCV) development pipeline.

IDX719: NS5A Program
Idenix announced today the initiation of a phase I clinical trial of the Company's NS5A inhibitor, IDX719. The first part of the study will evaluate safety, pharmacokinetics and food effect of IDX719 in 48 healthy volunteers. A subsequent part of the study will evaluate three days of IDX719 treatment in treatment-naïve genotype 1 HCV-infected patients and is expected to begin in the second quarter of 2012. Preclinical studies have shown that IDX719 has potent, pan-genotypic activity in vitro with the potential for once-daily dosing.

IDX19368 and IDX19370: Nucleotide Prodrug Program
Further, the Company has selected two additional nucleotide inhibitors, IDX19368 and IDX19370, as potential clinical candidates. The Company anticipates Investigational New Drug (IND) filings in mid-2012.

"Over the past year, Idenix has made significant progress in both our core nucleotide and NS5A programs," commented Ron Renaud, President and Chief Executive Officer of Idenix. "The preclinical profile of IDX719 is very competitive, and we are leveraging the Company's significant nucleotide chemistry expertise to discover novel nucleotides with promising properties as well as continuing to strengthen our IP position. We are excited about the potential of our novel antiviral compounds in the evolving HCV field in the coming year."

2011 Year-end Cash Balance
Idenix today reported that it ended 2011 with approximately $118.3 million of cash and cash equivalents. The Company's 2011 financial results have not yet been
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
2. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
3. Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab
4. Idenix Pharmaceuticals to Present at the JP Morgan 27th Annual Healthcare Conference
5. Idenix to Host Conference Call Discussing Fourth Quarter 2008 Financial Results
6. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
7. Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
8. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
9. Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
10. Idenix Pharmaceuticals Reports First Quarter Financial Results
11. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies addressing ... that it has been granted a patent by ... its unique delivery system for delivering its "original" ... for the treatment of diseases with an inflammatory ...
(Date:9/17/2014)... Cary, N.C. (PRWEB) September 17, 2014 ... solutions that advances science and healthcare, has renewed its ... term. , As part of the agreement, Personify will ... with a sustained emphasis on recruitment analytics, including time-to-fill, ... decision to renew our agreement with Personify was based ...
(Date:9/17/2014)... , September 17, 2014 ... of action from a truly novel class ... MGB Biopharma, a biopharmaceutical company developing ... today that it has secured £4.0m ($6.4m) ... antibacterial, MGB-BP-3, against a range of Gram-positive ...
(Date:9/17/2014)... Wilmington, DE (PRWEB) September 17, 2014 ... profit organization committed to lowering the barriers to ... has announced the appointment of Carmen Nitsche as ... organization looks to expand its global reach. , ... she was Vice President, Corporate Development. At Accelrys, ...
Breaking Biology Technology:RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4Beckman Coulter Signs 3-year RPO Contract with Personify 2Beckman Coulter Signs 3-year RPO Contract with Personify 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Pistoia Alliance Expands Business Development with Appointment of Carmen Nitsche 2
... France, October 13 ,Following fulfillment of all the ... all outstanding shares of Satisloh Holding,AG, the world ... and markets antireflective coating units and surfacing,machines, as ... million in revenue in 2007 and employs more ...
... 12 Mentice, Inc., a,leading developer and ... systems and Education Management Solutions, Inc. (EMS), ... software solutions, today,announced at the Transcatheter Cardiovascular ... that enables Mentice to market,MenticeSIM(TM) as a ...
... Cell Therapeutics, Inc.,(CTI) (Nasdaq and MTA: CTIC) announced ... with the NASDAQ Listing Qualifications Panel to present ... 4450(b)(1)(A),which requires a minimum market value of listed ... Letter from The NASDAQ Stock Market LLC,on October ...
Cached Biology Technology:Mentice, Inc. and Education Management Solutions, Inc. Form OEM Partnership 2Mentice, Inc. and Education Management Solutions, Inc. Form OEM Partnership 3Cell Therapeutics to Request a Hearing With NASDAQ Following Receipt of Staff Determination Letter 2Cell Therapeutics to Request a Hearing With NASDAQ Following Receipt of Staff Determination Letter 3
(Date:9/17/2014)... learned a great deal about complex social behavior by ... something to teach too. , With their unusually large ... parrots live in a complex social environment---not merely in ... or ants, but in a dynamic setting of alliances ... intelligent mammals: dolphins, whales, primates, and social carnivores, like ...
(Date:9/16/2014)... September, 2014)More than $100 trillion in cumulative public ... carbon dioxide (CO2)a 40 percent reduction of urban ... the world expands public transportation, walking and cycling ... by the University of California, Davis, and the ... , Further, an estimated 1.4 million early deaths ...
(Date:9/16/2014)... Ore. -- Each tree species has its own bacterial ... and colleagues from other institutions who studied the genetic ... on a Panamanian island. , "This study demonstrates for ... families and with different ecological strategies possess very different ... W. Kembel, a former postdoctoral researcher in the UO,s ...
Breaking Biology News(10 mins):Being social: Learning from the behavior of birds 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5Microbiome research shows each tree species has a unique bacterial identity 2
... up a large fraction of known plant viruses and ... to crop plants throughout the world. New details of ... by scientists using a variety of sophisticated imaging techniques ... and collaborating institutions. These findings, just published in ...
... GSK company focused on discovering and developing small molecule ... 2 Diabetes, announced today that it published a new ... and its potential to treat diseases of aging such ... heart disease. Entitled "SIRTUINS Novel Therapeutic Targets ...
... articles that will be published in the October 2008 ... Community Ecology: A Hybrid Beast with a Molecular Master. ... Thomas D. Bruns. , DNA-based techniques have in recent ... the first time. Results show extremely high diversity and ...
Cached Biology News:Structures of important plant viruses determined 2Structures of important plant viruses determined 3Sirtris' review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery 2BioScience tip sheet, October 2008 2BioScience tip sheet, October 2008 3
... Printing Kit contains choice of Printing Surface (3 glass ... Ti adhesion layer, 1 silicon wafer coated with 1000 ... plain glass slides) and PDMS Stamps (3 PDMS micropatterned ... or 100 um x 10 mm or 200 um ...
LTBP-1 (E-20)...
Anti-human CD48/BLAST-1, clone MEM102, Monoclonal Antibody...
Recognizes Kir4.1. The epitope does not share homology with any other known proteins.,SPECIES REACTIVITIES: The antibody is also expected to work with mouse and human due to sequence homology. Oth...
Biology Products: